ReviewJournal of clinical and experimental hepatology2016
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.
Review in Journal of clinical and experimental hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus.Clinical and experimental hepatology · 2020Article
- Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.PloS one · 2019Article
- Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.The International journal on drug policy · 2018Article
- Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India.Journal of clinical and experimental hepatology · 2018Article
- INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.Journal of clinical and experimental hepatology · 2018Review
- Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia.BMJ open gastroenterology · 2018Article
- Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation.Journal of clinical and experimental hepatology · 2017Article
- Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major.Journal of clinical and experimental hepatology · 2017Article
- Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2017Article
- Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?Journal of clinical and experimental hepatology · 2017Review
- Comments: Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy against HCV Infection: Update 2016.Journal of clinical and experimental hepatology · 2016Article
- Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients.Perspectives in clinical researchArticle
- Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.Journal of clinical and experimental hepatologyArticle
- Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.